Study to Evaluate Efficacy, Safety and Tolerability of HM15211(Efocipegtrutide) in Subjects

Recruiting

Phase 2

HM15211Study to Evaluate Efficacy, Safety and Tolerability of HM15211(Efocipegtrutide) in Subjects

Sponsor:

Hanmi Pharmaceutical Company Limited

Code:

NCT04505436

Conditions

NASH - Nonalcoholic Steatohepatitis

Eligibility Criteria

Sex: All

Age: 18 - 70

Healthy Volunteers: Not accepted

Interventions

HM15211

Placebo of HM15211

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-06-01. This information was provided to ClinicalTrials.gov by Hanmi Pharmaceutical Company Limited on 2025-03-21.